Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Pariser

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Journal of Drugs in Dermatology : JDD|July 26, 2013
Onchomycosis: an overviewBoni E Elewski, Phoebe Rich, Antonella Tosti, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline InfectionDavid M Pariser, Martin E Wendelken, Anthony M Rycerz, et al.
Journal of the American Podiatric Medical Association|September 26, 2015
Diagnosis and Management of Onychomycosis: Perspectives from a Joint Podiatry-Dermatology RoundtableBryan C Markinson, Tracey C Vlahovic, Warren S Joseph, et al.
Journal of Drugs in Dermatology : JDD|September 11, 2015
Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry RoundtableRichard K Scher, Antonella Tosti, Warren S Joseph, et al.
Pediatric Dermatology|March 10, 2020
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension studyAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
The Journal of Clinical and Aesthetic Dermatology|February 11, 2020
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity StudyDavid M Pariser, Lawrence J Green, Edward L Lain, et al.
Journal of the American Podiatric Medical Association|April 1, 2016
Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology RoundtableTracey C Vlahovic, Warren S Joseph, Richard K Scher, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Clinical Pharmacology and Therapeutics|June 23, 2019
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe PsoriasisGerard Bruin, Anke Hasselberg, Irina Koroleva, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Onychomycosis: Strategies to Minimize RecurrenceAditya K Gupta, Boni E Elewski, Ted Rosen, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Journal of Drugs in Dermatology : JDD|July 26, 2013
Onchomycosis: an overviewBoni E Elewski, Phoebe Rich, Antonella Tosti, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline InfectionDavid M Pariser, Martin E Wendelken, Anthony M Rycerz, et al.
Journal of the American Podiatric Medical Association|September 26, 2015
Diagnosis and Management of Onychomycosis: Perspectives from a Joint Podiatry-Dermatology RoundtableBryan C Markinson, Tracey C Vlahovic, Warren S Joseph, et al.
Journal of Drugs in Dermatology : JDD|September 11, 2015
Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry RoundtableRichard K Scher, Antonella Tosti, Warren S Joseph, et al.
Pediatric Dermatology|March 10, 2020
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension studyAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
The Journal of Clinical and Aesthetic Dermatology|February 11, 2020
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity StudyDavid M Pariser, Lawrence J Green, Edward L Lain, et al.
Journal of the American Podiatric Medical Association|April 1, 2016
Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology RoundtableTracey C Vlahovic, Warren S Joseph, Richard K Scher, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Clinical Pharmacology and Therapeutics|June 23, 2019
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe PsoriasisGerard Bruin, Anke Hasselberg, Irina Koroleva, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Onychomycosis: Strategies to Minimize RecurrenceAditya K Gupta, Boni E Elewski, Ted Rosen, et al.
Pageof 12